Intellia Therapeutics (NTLA) FCF Margin (2016 - 2025)
Historic FCF Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 558.18%.
- Intellia Therapeutics' FCF Margin rose 3870100.0% to 558.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 717.27%, marking a year-over-year increase of 1253600.0%. This contributed to the annual value of 612.78% for FY2024, which is 5121600.0% up from last year.
- Intellia Therapeutics' FCF Margin amounted to 558.18% in Q3 2025, which was up 3870100.0% from 701.02% recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' FCF Margin registered a high of 4933.44% during Q4 2023, and its lowest value of 23186.67% during Q3 2021.
- Over the past 5 years, Intellia Therapeutics' median FCF Margin value was 701.02% (recorded in 2025), while the average stood at 1610.84%.
- Per our database at Business Quant, Intellia Therapeutics' FCF Margin crashed by -230550000bps in 2021 and then surged by 225627900bps in 2022.
- Quarter analysis of 5 years shows Intellia Therapeutics' FCF Margin stood at 447.48% in 2021, then tumbled by -54bps to 690.94% in 2022, then surged by 814bps to 4933.44% in 2023, then tumbled by -114bps to 669.38% in 2024, then grew by 17bps to 558.18% in 2025.
- Its last three reported values are 558.18% in Q3 2025, 701.02% for Q2 2025, and 900.13% during Q1 2025.